Svetlana Gingis-Velitski
Overview
Explore the profile of Svetlana Gingis-Velitski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
750
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Almon E, Khoury T, Drori A, Gingis-Velitski S, Alon S, Chertkoff R, et al.
J Immunol Methods
. 2017 Apr;
446:21-29.
PMID: 28392436
Background: An orally administered BY-2 plant cell-expressed recombinant anti-TNF fusion protein (PRX-106) consists of the soluble form of the human TNF receptor (TNFR) fused to the Fc component of a...
2.
Ilan Y, Gingis-Velitski S, Ben Yaaco A, Shabbat Y, Zolotarov L, Almon E, et al.
Immunobiology
. 2016 Nov;
222(3):544-551.
PMID: 27832933
Aim: To evaluate the immune modulatory effect of the oral administration of plant cells expressing PRX-106. Methods: Mice treated with Concanavalin A (ConA) to induce immune hepatitis was orally treated...
3.
Ilan Y, Ben Yaacov A, Shabbat Y, Gingis-Velitski S, Almon E, Shaaltiel Y
World J Gastroenterol
. 2016 Nov;
22(39):8760-8769.
PMID: 27818591
Aim: To evaluate the immunomodulatory effect of oral administration of PRX-106 in the high-fat diet model. Methods: For 22 wk, C57BL/6 HFD-fed mice received daily oral treatments with BY-2 cells...
4.
Alishekevitz D, Gingis-Velitski S, Kaidar-Person O, Gutter-Kapon L, Scherer S, Raviv Z, et al.
Cell Rep
. 2016 Oct;
17(5):1344-1356.
PMID: 27783948
While chemotherapy strongly restricts or reverses tumor growth, the response of host tissue to therapy can counteract its anti-tumor activity by promoting tumor re-growth and/or metastases, thus limiting therapeutic efficacy....
5.
Tekoah Y, Shulman A, Kizhner T, Ruderfer I, Fux L, Nataf Y, et al.
Plant Biotechnol J
. 2015 Jun;
13(8):1199-208.
PMID: 26102075
Protalix Biotherapeutics develops recombinant human proteins and produces them in plant cell culture. Taliglucerase alfa has been the first biotherapeutic expressed in plant cells to be approved by regulatory authorities...
6.
Shaaltiel Y, Gingis-Velitski S, Tzaban S, Fiks N, Tekoah Y, Aviezer D
Plant Biotechnol J
. 2015 Apr;
13(8):1033-40.
PMID: 25828481
Gaucher's disease (GD), a lysosomal storage disorder caused by mutations in the gene encoding glucocerebrosidase (GCD), is currently treated by enzyme replacement therapy (ERT) using recombinant GCD that is administered...
7.
Fremder E, Munster M, Aharon A, Miller V, Gingis-Velitski S, Voloshin T, et al.
Int J Cancer
. 2013 Dec;
135(2):270-81.
PMID: 24347266
Acute chemotherapy can induce rapid bone-marrow derived pro-angiogenic cell (BMDC) mobilization and tumor homing, contributing to tumor regrowth. To study the contribution of tumor cells to tumor regrowth following therapy,...
8.
Benayoun L, Schaffer M, Bril R, Gingis-Velitski S, Segal E, Nevelsky A, et al.
Cancer Biol Ther
. 2012 Nov;
14(1):64-74.
PMID: 23114641
Tumor relapse and tumor cell repopulation has been explained partially by the drug-free break period between successive conventional treatments. Strategies to overcome tumor relapse have been proposed, such as the...
9.
Bertolini F, Mancuso P, Benayoun L, Gingis-Velitski S, Shaked Y
Methods Mol Biol
. 2012 Aug;
904:165-72.
PMID: 22890931
Results obtained from preclinical studies have shown that endothelial progenitor cells (EPCs) play a crucial role in tumor growth and metastasis. In the clinic, EPCs are present in the peripheral...
10.
Benayoun L, Gingis-Velitski S, Voloshin T, Segal E, Segev R, Munster M, et al.
Stem Cells
. 2012 Jul;
30(9):1831-41.
PMID: 22782858
Tumor-initiating cells (TICs) are a subtype of tumor cells believed to be critical for initiating tumorigenesis. We sought to determine the angiogenic properties of TICs in different tumor types including...